Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Alnylam Pharmaceuticals Inc | 571 |
| 2 | ModernaTx Inc | 161 |
| 3 | Amylin Pharmaceuticals LLC | 110 |
| 4 | Arbutus Biopharma Corp | 77 |
| 5 | Alza Corp | 70 |
| 6 | AstraZeneca Pharmaceuticals LP | 65 |
| 7 | Harvard University | 63 |
| 8 | Bayer Corp | 59 |
| 9 | Moderna Inc | 56 |
| 10 | Novo Nordisk AS | 55 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 3,442 |
| 2 | A61P | Therapeutic activity (drug indications) | 3,153 |
| 3 | C12N | Microorganisms, enzymes | 1,828 |
| 4 | C07K | Peptides | 1,582 |
| 5 | C07D | Heterocyclic compounds | 626 |
| 6 | G01N | Investigating / analysing materials | 609 |
| 7 | C07H | Sugars and derivatives | 418 |
| 8 | C12Y | Enzyme nomenclature (EC numbers) | 396 |
| 9 | Y02A | Climate change adaptation | 359 |
| 10 | A61Q | Cosmetics, personal care | 301 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Intermedin analogue prepared by bonding ring core sequence with biotin or cell-penetrating peptides | 2012 | ZHANG GA | 55 |
| THERAPEUTIC USES OF INTERMEDIN 47 AND 53 PEPTIDES | 2009 | Mondobiotech Laboratories AG | 6 |
| Therapeutic use of intermedin 47 peptide and intermedin 53 peptide | 2010 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 0 |
| THERAPEUTIC USES OF INTERMEDIN 47 AND 53 PEPTIDES | 2009 | Mondobiotech Laboratories AG | 0 |
| USE OF INTERMEDIN 47 PEPTIDE AS A THERAPEUTIC AGENT | 2009 | Mondobiotech Laboratories AG | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Regulation of Appetite and Obesity | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Akiyoshi Takahashi | Kitasato University | 9 |
| 2 | Hiroshi Kawauchi | Kitasato University | 8 |
| 3 | Helgi B. Schiöth | Uppsala University | 5 |
| 4 | Akikazu Yasuda | Suntory Foundation for Life Sciences | 4 |
| 5 | Liga Zvejniece | University of Latvia | 4 |
| 6 | Ludger Witte | Technische Universität Braunschweig | 4 |
| 7 | Maija Dambrova | Latvijas Organiskās Sintēzes Institūts | 4 |
| 8 | Robert M. Dores | University of Denver | 4 |
| 9 | Ruta Muceniece | University of Latvia | 4 |
| 10 | Tatjana Haitina | Uppsala University | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| A missense mutation disrupting a dibasic prohormone processing site in pro-opiomelanocortin (POMC) increases susceptibility to early-onset obesity through a novel molecular mechanism | 2002 | 291 | Regulation of Appetite and Obesity |
| A POMC variant implicates β-melanocyte-stimulating hormone in the control of human energy balance | 2006 | 236 | Regulation of Appetite and Obesity |
| Prevalence, Spectrum, and Functional Characterization of Melanocortin-4 Receptor Gene Mutations in a Representative Population-Based Sample and Obese Adults from Germany | 2006 | 208 | Regulation of Appetite and Obesity |
| A role for β-melanocyte-stimulating hormone in human body-weight regulation | 2006 | 186 | Regulation of Appetite and Obesity |
| An Alu Element–Associated Hypermethylation Variant of the POMC Gene Is Associated with Childhood Obesity | 2012 | 176 | Epigenetics and DNA Methylation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of beta-MSH?
What are the primary research topics associated with beta-MSH in the scientific literature?
Which organizations hold the most patents related to beta-MSH?
What are the main CPC classifications under which beta-MSH patents are filed?
How many leading authors have published research on beta-MSH and from which institutions?